Clinical Characteristics and Outcomes in the Very Elderly Patients Hospitalized for Acute Heart Failure: Importance of Pharmacologic Guideline Adherence

Shih-Hsien Sung1,5,6, Ta-Jung Wang7,8, Hao-Min Cheng2,4,5,6, Wen-Chung Yu1,4,5, Chao-Yu Guo6, Chern-En Chiang3,4,5 & Chen-Huan Chen2,4,5,6

The prognostic factors and pharmacological effects of the very elderly patients (aged ≥ 80 years) with acute heart failure (AHF) remain unclear. The study, therefore, investigated the prognostic impacts of the guideline-recommended pharmacological therapy in these patients. A cohort of 1297 very elderly patients [85.1 ± 4.0 years, 69.7% male, 32.6% heart failure with reduced left ventricular ejection fraction (LVEF), HFrEF], hospitalized for AHF, was studied. The percentage of the recommended prescription for HFrEF at discharge, including renin-angiotensin system inhibitors, β-blockers, and mineralocorticoid receptor antagonists, was calculated as guideline adherence indicator (GAI). Among the 1233 survivors at discharge, 495 subjects (40.1%) died during a mean follow-up of 27.1 ± 23.9 months. Mean GAI s in HFrEF and HFpEF were 70.6 ± 34.9% and 64.1 ± 35.9%, respectively. A higher GAI was associated with less overall mortality [hazard ratio and 95% confidence interval per-1SD: 0.781, 0.655–0.930] and cardiovascular death (0.718, 0.558–0.925), independent of age, gender, diabetes, hypertension, mean blood pressure, LVEF, eGFR, sodium, and NT-proBNP. A GAI of 100% was associated with a better survival in both HFrEF and HFpEF. A prescription of the three recommended medications for HFrEF to the very elderly AHF patients was associated with a better survival after discharge.

Age is a major risk factor for heart failure (HF), and HF related outcomes, including hospitalization and death1. The incidence and prevalence of HF increase sharply with age and survival is dismal following the development of HF, especially in the elderly1,2. Due to a better management of chronic and acute HF patients, the survival after a diagnosis of HF has been improved over the past 30 years1. The age-standardized death rate has declined by 40% and the mean age at death from HF has risen from 80.0 to 82.7 years in seven European countries during two decades4. Despite the improvements, the five-year observed survival was about 26–52% for HF and was worse than that of many cancers and HF continues to be responsible for a tremendous burden on health care systems4,5. Although the oldest old subjects (≥80 years) have the highest incidence, prevalence, and mortality of HF, the characteristics, management, and outcomes of the very elderly with HF have not been well described6 due to insufficient samples in most epidemiological surveys or registries6–10. The clinical picture of the octogenarian HF may differ substantially from that of the less old HF patients, because the progressive ventriculoarterial aging

1Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 2Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan. 3General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan. 4Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan. 5Department of Medicine, National Yang-Ming University, Taipei, Taiwan. 6Institute of Public Health, National Yang-Ming University, Taipei, Taiwan. 7Department of Medicine, Taipei Medical University Shuang Ho Hospital, Taipei, Taiwan. 8Department of Internal Medicine, Taipei Medical University, Taipei, Taiwan. Correspondence and requests for materials should be addressed to S.-H.S. (email: mr.sungsh@gmail.com) or C.-H.C. (email: chench@vghtpe.gov.tw)
lows the threshold for the development of HF. The better survival of women and those with heart failure and preserved ejection fraction (HFpEF) contributes to the higher prevalence of HFpEF in the elderly women.

More importantly, few landmark HF trials have included very elderly patients and thus yielded limited evidence of pharmacological therapies in the octogenarian HF patients. Furthermore, compared with younger patients, the older HF patients often have problems with multiple comorbidities, and underuse and underdosage of the recommended drugs, leading to suboptimal clinical outcomes. International guidelines are not frequently implemented in this population, neither. Whether the guideline-recommended treatments improve the clinical outcomes in the very elderly patients with HFrEF remains to be elucidated, especially when adverse drug events prevail among the very elderly. So far, no treatment has been shown to improve outcomes in patients with HFpEF. It is also unknown whether treatments recommended for HFrEF, including renin-angiotensin system (RAS) inhibitors, β-blockers, and mineralocorticoid receptor antagonists (MRAs), are tolerable for the oldest old HFpEF patients.

In the present study, we therefore investigated the prognostic impact of the guideline-recommended pharmacological therapy for HFrEF in the very elderly acute heart failure (AHF) patients, aged ≥80 years with HFrEF, as well as HFpEF.

Methods

A total of 1297 patients aged over 80 years who were hospitalized primarily for AHF at Taipei Veterans General Hospital during the period from October 1, 2003, to December 31, 2012, was identified from HARVEST registry. Patients with acute coronary syndrome, severe infection, severe hepatic disease, or active malignancy were excluded. Data of the index hospitalization on patient demographics, biochemistry, echocardiographic characteristics, co-morbidities, and medications, which have been prospectively registered in a web-based electronic medical recording system, were retrieved. The institutional review committee of Taipei Veterans General Hospital approved the use of the registry data for research purposes. Given the nature of an administrative registry, informed consent was waived.

Renal function, levels of serum electrolytes and N-terminal pro-B type natriuretic peptide (NT-proBNP) were measured at the presentations to the hospital. Lipid profiles were checked after 8 hours fasting in the next morning. Estimated glomerular filtration rate (eGFR) was calculated by the modified glomerular filtration rate estimating equation for Chinese patients. There were missing values for NT-proBNP because the commercialized kit for NT-proBNP (Roche Diagnostics, Basel, Switzerland) was available after 2009. Echocardiography was performed by experienced technicians and independently reviewed by the physicians during hospitalization. LVEF was derived from the 2D-guided M-mode echocardiography, and E/e' was calculated as the ratio of early ventricular filling flow velocity (E) to the septal mitral annulus tissue velocity (e'). HFrEF and HFpEF were defined by LVEF < 50% and LVEF ≥ 50%, respectively.

Pharmacological therapy and guideline adherence indicator. Medications on discharge were recorded. RAS inhibitors referred to either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. According to HF guidelines, all 3 classes of life-saving medications, namely, RAS inhibitors, β-blockers, and MRAs, should be prescribed to patients with HFrEF in the absence of contraindications. The contraindications are renal insufficiency (eGFR < 30 ml/min/1.73 m²) or hyperkalemia (K > 5.5 mEq/L) for RAS inhibitors and MRAs, and bronchial asthma or profound bradycardia for β-blockers. When a patient with HFrEF received all of the indicated HF medications, he or she was considered to be 100% adhering to the guidelines. A guideline adherence indicator (GAI) was therefore calculated by dividing the number of prescribed medications by the number of indicated medications in percentage. A GAI of 100% is considered to be complete adherence to the guidelines. Although the 3 classes of life-saving medications were not recommended to treat patients with HFpEF, a GAI was calculated for every patient.

Follow up. The primary endpoints of mortality were confirmed by linking the database to the National Death Registry. The National Death Registry database registers valid information according to the International Classification of Disease, Ninth Revision (ICD-9). The ICD-9 codes for cardiovascular death were 390–459.

Statistical methods. Continuous variables were expressed as mean ± standard deviation (SD) and comparisons between groups were conducted by the Student’s t-test. Categorical data were described by the absolute number and relative frequencies and compared by the chi-square test. The prognostic impact of GAI was analyzed using Kaplan–Meier accumulated survival curves. Multivariable Cox proportional hazards models were used to evaluate the independent predictors of mortality. Because the distribution of NT-proBNP was skewed, log transformation was conducted prior to Cox regression analysis. Subgroup analyses, stratified by age of 85 years, gender, the presence of diabetes, hypertension, or CAD, and renal function were conducted for GAI ≥ 100%. In addition, patients with either HFrEF or HFpEF were analyzed for the prognostic impacts of GAI = 100% and each class of the 3 drugs. All statistics were performed by using SPSS v.16.0 software (SPSS, Inc., Chicago, IL, USA). All the tests performed were two-sided, and a P value < 0.05 was considered statistically significant.

Results

Patient characteristics and outcomes. The baseline characteristics of the 1297 patients (85.1 ± 4.0 years, 69.7% of men) are displayed in Table 1. The most common comorbidities in the study population were hypertension (66.1%), atrial fibrillation (33.8%), diabetes mellitus (31.9%), and coronary artery disease (27.9%), respectively. Comparing to patients with HFrEF (32.6%), patients with HFpEF were slightly older, more likely to be women, and had higher systolic blood pressure, pulse pressure, and lower heart rate at their presentation to the hospital. Hypertension was more prevalent in HFpEF, whereas coronary artery disease was more prevalent in HFrEF. In addition, HFpEF had higher E/e', lower sodium levels, and lower NT-proBNP, in comparison to HFrEF.

chi-square test. The prognostic impact of GAI was analyzed using Kaplan–Meier accumulated survival curves. Multivariable Cox proportional hazards models were used to evaluate the independent predictors of mortality. Because the distribution of NT-proBNP was skewed, log transformation was conducted prior to Cox regression analysis. Subgroup analyses, stratified by age of 85 years, gender, the presence of diabetes, hypertension, or CAD, and renal function were conducted for GAI ≥ 100%. In addition, patients with either HFrEF or HFpEF were analyzed for the prognostic impacts of GAI = 100% and each class of the 3 drugs. All statistics were performed by using SPSS v.16.0 software (SPSS, Inc., Chicago, IL, USA). All the tests performed were two-sided, and a P value < 0.05 was considered statistically significant.

Results

Patient characteristics and outcomes. The baseline characteristics of the 1297 patients (85.1 ± 4.0 years, 69.7% of men) are displayed in Table 1. The most common comorbidities in the study population were hypertension (66.1%), atrial fibrillation (33.8%), diabetes mellitus (31.9%), and coronary artery disease (27.9%), respectively. Comparing to patients with HFrEF (32.6%), patients with HFpEF were slightly older, more likely to be women, and had higher systolic blood pressure, pulse pressure, and lower heart rate at their presentation to the hospital. Hypertension was more prevalent in HFpEF, whereas coronary artery disease was more prevalent in HFrEF. In addition, HFpEF had higher E/e', lower sodium levels, and lower NT-proBNP, in comparison to HFrEF.
Baseline clinical characteristics of the study population, stratified by left ventricular ejection fraction.

|                     | Total n = 1297 | HFrEF n = 423 | HfPEF n = 874 | P value |
|---------------------|----------------|---------------|---------------|---------|
| Age, (year)         | 85.1 ± 4.0     | 84.5 ± 3.8    | 85.4 ± 4.0    | <0.001  |
| Male, n (%)         | 904 (69.7)     | 331 (78.3)    | 573 (65.6)    | <0.001  |

Vital signs at the first presentation

|                     | Total n = 1297 | HFrEF n = 423 | HfPEF n = 874 | P value |
|---------------------|----------------|---------------|---------------|---------|
| SBP, mmHg           | 147 ± 32       | 141 ± 30      | 149 ± 33      | <0.001  |
| MAP, mmHg           | 102 ± 21       | 100 ± 21      | 102 ± 21      | 0.133   |
| PP, mmHg            | 67 ± 25        | 61 ± 22       | 70 ± 26       | <0.001  |
| Heart rate, beats/minute | 90 ± 25   | 96 ± 27       | 87 ± 24       | <0.001  |

Comorbidity, n (%)

|                     | Total n = 1297 | HFrEF n = 423 | HfPEF n = 874 | P value |
|---------------------|----------------|---------------|---------------|---------|
| Hypertension        | 857 (66.1)     | 253 (59.8)    | 604 (69.1)    | 0.001   |
| Diabetes mellitus   | 414 (31.9)     | 133 (31.2)    | 281 (32.2)    | 0.797   |
| Coronary artery disease | 362 (27.9) | 152 (35.9)    | 210 (24.0)    | <0.001  |
| Atrial fibrillation | 438 (33.8)     | 150 (35.5)    | 288 (33.0)    | 0.370   |

Echocardiogram

|                     | Total n = 1297 | HFrEF n = 423 | HfPEF n = 874 | P value |
|---------------------|----------------|---------------|---------------|---------|
| Left atrial diameter, cm | 4.5 ± 0.9   | 4.5 ± 0.9     | 4.6 ± 0.9     | 0.271   |
| LVEF, %             | 57.0 ± 20.5   | 34.7 ± 18.1   | 67.8 ± 10.4   | <0.001  |
| RVSP, mmHg          | 42.9 ± 15.7   | 44.9 ± 8.8    | 45.5 ± 15.5   | 0.151   |
| E'/e'               | 17.4 ± 7.6    | 16.5 ± 7.1    | 19.4 ± 8.3    | <0.001  |

Laboratory data

|                     | Total n = 1297 | HFrEF n = 423 | HfPEF n = 874 | P value |
|---------------------|----------------|---------------|---------------|---------|
| eGFR, ml/min/1.73m² | 52.6 ± 26.6    | 52.2 ± 22.8   | 52.9 ± 28.3   | 0.670   |
| Hemoglobin, mg/dL   | 11.4 ± 2.0     | 11.9 ± 1.9    | 11.2 ± 2.0    | <0.001  |
| Sodium, mEq/L       | 138.7 ± 5.1    | 139.1 ± 4.7   | 138.5 ± 5.3   | 0.041   |
| Potassium, mEq/L    | 4.1 ± 0.7      | 4.0 ± 0.6     | 4.1 ± 0.7     | 0.082   |
| *NT-proBNP, ng/L (n = 599) | 5392 ± 3.7 | 9325 ± 2.7    | 4072 ± 3.9    | <0.001  |

Table 1. Baseline clinical characteristics of the study population, stratified by left ventricular ejection fraction.

*Geometric mean and standard deviation. E/e’ = ratio of early ventricular filling flow velocity (E) to the septal mitral annulus tissue velocity (‘e’); eGFR = estimated glomerular filtration rate; HfPEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; MAP = mean arterial blood pressure; NT-proBNP = N-terminal prohormone brain natriuretic peptide; PP = pulse pressure; RVSP = right ventricular systolic pressure; SBP = systolic blood pressure.

Predictors of mortality in acute heart failure.

HFpEF and HFrEF had similar mean arterial blood pressure, left atrial diameter, right ventricular systolic blood pressure, eGFR, and prevalence of diabetes mellitus and atrial fibrillation.

In total, 64 inpatient deaths were recorded (4.9%). Among the 1233 survivors, 495 post-discharge deaths were observed during a mean follow-up of 27.1 ± 23.9 months. Table 2 reveals the on-discharge major pharmacotherapy and guideline adherence indicator of the index hospitalization survivors (n = 1233). HFrEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; MRAs = Mineralocorticoid receptor antagonists; RAS inhibitors = renin-angiotensin system inhibitors, including angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists.

Univariate analyses, older age, lower LVEF, eGFR, sodium, GAI, and higher NT-proBNP were significantly associated with post-discharge mortality in the whole study population (Supplementary Table S1). In the whole study population and the group of HFrEF, patients...
coronary artery disease, and renal function, independent of age, gender, LVEF, and eGFR (Fig. 2).

... of total mortality across various subpopulations, stratified by age, gender, presence of diabetes, hypertension, or pressure, left ventricular ejection fraction, estimated glomerular filtration rate and sodium (Table 3, Model 1).

... 0.754–0.935 and 0.718, 0.558–0.925, respectively) (Table 3, Model 2).

... difference became borderline significant (P = 0.053) at the end of the 3-year follow-up (Fig. 1C).

... higher GAI was independently associated with lower mortality and cardiovascular death in the whole study population (hazard ratio and 95% confidence interval per-1SD: 0.840, 0.754–0.935 and 0.842, 0.712–0.996, respectively), after accounting for age, gender, diabetes mellitus, hypertension, mean blood pressure, left ventricular ejection fraction, estimated glomerular filtration rate and sodium (Table 3, Model 1). With a further adjustment for NT-proBNP, GAI remained significantly associated with total and cardiovascular mortality (0.781, 0.655–0.930 and 0.718, 0.558–0.925, respectively) (Table 3, Model 2).

The subgroup analyses demonstrated that a GAI of 100% was consistently associated with a similar reduction of total mortality across various subpopulations, stratified by age, gender, presence of diabetes, hypertension, or coronary artery disease, and renal function, independent of age, gender, LVEF, and eGFR (Fig. 2).

Pharmacotherapy and mortality in HFrEF and HFP EF. With adjustments for age, gender, LVEF and eGFR, the on-discharge individual prescriptions of RAS inhibitors, β-blockers, and MRAs were significantly associated with a reduction of 1-year overall mortality in the total study population by 40.3%, 39.3%, and 40.5%, respectively, and also in patients with HFrEF (by 41%, 35.7%, and 55.2%, correspondingly) and HFP EF (by 40%, 42.8%, and 32.2%, correspondingly) (Fig. 3A). However, only β-blockers and MRAs but not RAS inhibitors were independently associated with a reduction of 3-year overall mortality in the total study population and in HFP EF (Fig. 3B). In HFP EF, only the prescription of β-blockers was independently associated with a better 3-year overall survival. In contrast, a GAI of 100% was consistently associated with a significantly lower 1-year and 3-year overall mortality in the whole study population, and also in the groups of HFrEF and HFP EF, independent of age, gender, LVEF and eGFR (Fig. 3A,B).

Discussions

In this large very elderly cohort of patients hospitalized due to AHE, we found that HFP EF was more prevalent than HFrEF, but HFP EF and HFR EF shared similar clinical characteristics, comorbidities, echocardiographic findings, laboratory data, and even on-discharge medications, with some significant but small absolute differences. The on-discharge prescription of the 3 guidelines-recommended medications for HFrEF, was significantly and independently associated with post-discharge mortality in the very elderly AHE patients, with either HFrEF or HFP EF. In particular, the study results suggest that RAS inhibitors, β-blockers and MRAs may offer survival benefits at one year after discharge, and β-blockers may have prolonged survival benefits in both HFrEF and HFP EF. Thus, the results may encourage the guideline adherent pharmacological therapies in the very elderly HF patients to improve survival.

Prognosis of the very elderly with acute heart failure. It has been noticed that the survival of the octogenarians with AHE was dismal, compared with patients of age <80 years. The European heart failure surveys have demonstrated the octogenarians were used to have multiple co-morbidities, preserved LVEF, and higher
mortality at both 12-week and 1-year follow-up duration. Comparing with the 1-year mortality rate in European heart failure survey II of 28.4%, the post-discharge mortality rate in this study was 21.4% at 1-year, 36.7% at 2-year and 40.1% at 3-year follow-up. In addition to co-morbidities and medications, Komajda et al. suggested age and renal function were the independent baseline characteristics related to mortality. In the present study, we further showed that LVEF, serum sodium and NT-proBNP levels, as well as age and eGFR, were independently related to long-term mortality. Although it has been suggested patients with either HFrEF or HFpEF shared similar risks of mortality, the growing evidence may support the findings that LVEF was related to clinical outcomes. Hyponatremia has been correlated with the prognosis of patients hospitalized for acute HF that a lower on-admission serum sodium level was related with a worse outcome. While Barsheshet et al. have shown the prognostic discrepancies of hyponatremia in patients of ≤75 years or >75 years, the present study expands that hyponatremia remains predictive of mortality in this very elderly population with acute HF.

**Guideline adherent prescriptions and mortality.** Based on the recommendations from clinical trials, pharmacological therapies including RAS inhibitors, β-blockers, and MRAs may attenuate the clinical risks of mortality and morbidity in patients with HFrEF. While the majority of the clinical trials have excluded octogenarians, the present study suggested the guideline-adherent medications may save lives in the very elderly population with HFrEF.

Although RAS inhibitors, including ACE inhibitors and ARBs, have been beneficial to all stages of HFrEF, Flather et al. demonstrated an attenuated effect of ACE inhibitors on mortality and morbidity with increasing age in a meta-analysis of 12763 chronic HF subjects with reduced LVEF. In a mean follow-up duration of 35 months, ACE inhibitors were not related to death, hospitalization for HF, or myocardial infarction in patients aged >75 years. In contrast, Masoudi et al. showed the 1-year survival benefit of ACE inhibitors persisted across all age subpopulations of acute HF, including subjects over 85 years. In the present study, the prescription of RAS inhibitors was independently associated with a lower 1-year but not 3-year mortality in the very elderly patients, which may echo that the survival benefit of RAS inhibitors may attenuate with a longer follow-up duration.

In a meta-analysis of 12729 subjects with chronic HF, Dulin et al. proposed that the elderly may get equal benefits from β-blockers, comparing to the non-elderly patients. Nebivolol was associated with a 14% reduction of primary endpoints in the elderly HF patients of >70 years. In a propensity-matched cohort of acute HF patients, the use of β-blockers was associated with lower 30-day and 4-year post-discharge mortality in the elderly of Medicare beneficiaries. The present study further extends that the on-discharge prescription of β-blockers was independently associated with better 1-year and 3-year survival in the very elderly patients with HFrEF.

The survival advantage of MRAs in HFrEF has been documented in RALES and EPHESUS trial, and the subgroup analyses suggested that the elderly (defined by ≥65, ≥67, or ≥75 years) had comparative benefits with MRAs. The present study furthers our understandings that MRAs may prolong survival even in the very elderly HFrEF patients.

**Pharmacological therapy for HFpEF.** RAS inhibitors have not been proven to improve survival in HFpEF. On the other hand, the PEP-CHF trial, composed of patients ≥70 years with HFpEF, demonstrated modest clinical benefits of ACE inhibitors at 1 year. In a cohort of 438 Chinese HFpEF patients (mean age...
spironolactone group 45. Furthermore, Patel et al. demonstrated a real-world data that spironolactone might be associated with a favorable effect in HFpEF patients aged ≥ 80 years 46. Similarly, the present study suggests that the prescription of MRAs may be beneficial in the very elderly HFpEF patients.

There were several limitations in this study. First, given the nature of an observational study of a single-center registry, there was a selection bias arising from unobserved variables. However, we have adjusted all available confounders to show the independent prognostic value of each potential predictor. The prognostic effects of RAS inhibitors, β-blockers and MRAs have been adjusted with age, gender, LVEF and eGFR accounting for age, gender, left ventricular ejection fraction, and estimated glomerular filtration rate. HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction.

64.7 ± 9.6 years), the prescription of angiotensin-converting enzyme inhibitors was associated with a significant decrease in overall mortality during a long-term follow-up 48. The present study also supports that the prescription of RAS inhibitors may improve the 1-year survival of the very elderly HFpEF patients. The effectiveness of β-blockers in the management of HFpEF has not been established. Two large observational trials of 11326 and 11959 elderly acute HF patients (mean age 73.9 and 78.4 years in Kaiser Permanente of Northern California and Medicare beneficiaries of north Carolina), respectively, proposed that the use of β-blockers was associated with favorable outcomes in a composite population of HFrEF and HFrEF 39,40. A meta-analysis comprising 12 studies and 21206 subjects with HFpEF demonstrated that treatment with β-blockers was related to a significant reduction of mortality, both in patients < 65 and ≥ 65 years 41. Although conflict results exist 42, the present study also showed a survival benefit of β-blockers in the very elderly patients with HFpEF up to 3 years follow-up. The result may encourage a therapeutic trial of β-blockers in the management of HFpEF in octogenarians.

While MRAs may significantly improve left ventricular diastolic function and serum markers of cardiac fibrosis in patients with HFpEF 43,44, the prognostic impact of MRAs in HFpEF was not as encouraging in the TOPCAT trial 45. Although spironolactone did not reduce mortality, hospitalization for HF was significantly lower in the spironolactone group 46. Furthermore, Patel et al. demonstrated a real-world data that spironolactone might be associated with a favorable effect in HFpEF patients aged ≥ 80 years 46. Similarly, the present study suggests that the prescription of MRAs may be beneficial in the very elderly HFpEF patients.

There were 38 patients in this dataset with severe valvular heart disease in this study, including severe AS, severe AR, and severe MR, while surgery or transcatheter therapy might affect the prognosis. However, GAI was independently related to the long-term mortality in patients without severe valvular heart disease (0.841, 0.745–0.949), after accounting for age, gender, diabetes mellitus, hypertension, mean blood pressure, LVEF, eGFR, and sodium.

### Study Limitations

There were several limitations in this study. First, given the nature of an observational study of a single-center registry, there was a selection bias arising from unobserved variables. However, we have adjusted all available confounders to show the independent prognostic value of each potential predictor. The prognostic effects of RAS inhibitors, β-blockers and MRAs have been adjusted with age, gender, LVEF and eGFR accounting for age, gender, left ventricular ejection fraction, and estimated glomerular filtration rate. HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction.
Conclusions
Guidelines-adherent prescriptions for HFrEF may prolong survival in the very elderly acute HF patients. Very elderly patients with acute HFrEF may also benefit from the RAS inhibitors, β-blockers, and MRAs. The study results may encourage physicians to prescribe the guidelines-recommended life-saving medications to the very elderly patients with HF.

References
1. Liu, L. & Eisen, H. J. Epidemiology of heart failure and scope of the problem. Cardiology clinics 32, 1–8, https://doi.org/10.1016/j.ccl.2013.09.009 (2014).
2. van Riet, E. E. et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. European journal of heart failure 18, 242–252, https://doi.org/10.1002/ejhf.483 (2016).
3. Larbi, S. et al. Trends in death attributed to heart failure over the past two decades in Europe. Eur J Heart Fail 14, 234–239, https://doi.org/10.1093/ejhf/hfu182 (2012).
4. Askoxylakis, V. et al. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC cancer 10, 105, https://doi.org/10.1186/1471-2407-10-105 (2010).
5. Komajda, M. et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. European heart journal 30, 478–486, https://doi.org/10.1093/eurheartj/ehn539 (2009).
6. Hamaguchi, S. et al. Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure-A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (J-CARE-CARD). Journal of cardiology 62, 95–101, https://doi.org/10.1016/j.jcc.2013.03.009 (2013).
7. Adams, K. F. Jr. et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart J. 149, 209–216, https://doi.org/10.1016/j.ahj.2004.08.005 (2005).
8. Gheorghiade, M. et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296, 2217–2226 (2006).
9. Abraham, W. T. et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 52, 347–356, https://doi.org/10.1016/j.jacc.2008.04.028 (2008).
10. Atherton, J. J. et al. Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). J Card Fail 18, 82–88, https://doi.org/10.1016/j.cardfail.2011.09.003 (2012).
11. Metra, M., Dei Cas, L. & Massie, B. M. Treatment of heart failure in the elderly: never say it’s too late. European heart journal 30, 391–393, https://doi.org/10.1093/eurheartj/eup024 (2009).
12. Meta-analysis Global Group in Chronic Heart, P. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur. Heart J. 33, 1750–1757, https://doi.org/10.1093/eurheartj/ehr254 (2012).
13. Maggioni, A. P. et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,640 patients of the ESC Heart Failure Long-Term Registry. European journal of heart failure 15, 1373–1384, https://doi.org/10.1002/ejhf.hfi134 (2013).
14. Komajda, M. et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. European heart journal 26, 1653–1659, https://doi.org/10.1093/eurheartj/ehi251 (2005).
15. Yoo, B. S. et al. Survey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World (SUGAR): a multi-center, retrospective, observational study. PLoS One 9, e86596, https://doi.org/10.1371/journal.pone.0086596 (2014).
16. Yancy, C. W. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62, e147–239, https://doi.org/10.1016/j.jacc.2013.05.019 (2013).
17. McMurray, J. J. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33, 1787–1847, https://doi.org/10.1093/eurheartj/ehv104 (2012).
18. Sztarko, R., Chau, V. & Wong, R. Adverse drug events and associated factors in heart failure therapy among the very elderly patients. Can Geriatr J. 14, 79–92, https://doi.org/10.5770/cgj.v14i4.19 (2011).
19. Cheng, Y. I. et al. Prognostic Nutritional Index and the Risk of Mortality in Patients With Acute Heart Failure. J Am Heart Assoc 6, https://doi.org/10.1161/JAHA.116.004876 (2017).
20. Ma, Y. C. et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J. Am. Soc. Nephrol. 17, 2937–2944, https://doi.org/10.1681/ASN.2006040368 (2006).
21. Teichholz, L. E., Kreulen, T., Herman, M. V. & Gorlin, R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 37, 7–11 (1976).
22. Stromer, H. & Camerer, M. Adherence to guidelines is a predictor of outcome in chronic heart failure: the Mahler survey. European heart journal 27, 247–248, https://doi.org/10.1093/eurheartj/ehq575 (2006).
23. Sung, S. H. et al. White coat hypertension is more risky than prehypertension: important role of arterial wave reflections. Hypertension 61, 1346–1353, https://doi.org/10.1161/HYPERTENSIONAHA.111.05659 (2013).
24. Bhatia, R. S. et al. Outcome of heart failure with preserved ejection fraction in a population-based study. The New England journal of medicine 355, 260–269, https://doi.org/10.1056/NEJMoa05130 (2006).
25. Coles, A. H. et al. Magnitude of and Prognostic Factors Associated With 1-Year Mortality After Hospital Discharge for Acute Decompensated Heart Failure Based on Ejection Fraction Findings. Journal of the American Heart Association 4, https://doi.org/10.1161/JAHA.115.002303 (2015).
26. Rusinaru, D. et al. Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis (dogger): Meta-Analysis Global Group in Chronic heart failure (MAGGIC). European journal of heart failure 14, 1139–1146, https://doi.org/10.1093/ejhf/hfh099 (2012).
27. Lee, D. S. et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. Jama 290, 2581–2587, https://doi.org/10.1001/jama.290.19.2581 (2003).
28. Barsheeshet, A. et al. Predictors of long-term (4-year) mortality in elderly and young patients with acute heart failure. Eur. J. Heart Fail. 12, 833–840, https://doi.org/10.1093/ejhf/hgt079 (2010).
29. Roth, G. A. et al. Use of Guideline-Directed Medications for Heart Failure Before Cardioverter-Defibrillator Implantation. Journal of the American College of Cardiology 67, 1062–1069, https://doi.org/10.1016/j.jacc.2015.12.046 (2016).
30. Flather, M. D. et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355, 1575–1581 (2000).
31. Masoudi, F. A. et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. *Circulation* **110**, 724–731, https://doi.org/10.1161/01.cir.0000138934.28340.ed (2004).

32. Dulin, B. R., Haas, S. J., Abraham, W. T. & Krum, H. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials. *The American Journal of Cardiology* **95**, 896–898, https://doi.org/10.1016/S0002-9149(00)00459-4 (2000).

33. Fletter, M. D. et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *European heart journal* **26**, 215–225, https://doi.org/10.1093/eurheartj/ehi115 (2005).

34. Bhatia, V. et al. Beta-blocker Use and 30-Day All-cause Readmission in Medicare Beneficiaries With Systolic Heart Failure. *The American journal of medicine* **128**, 715–721, https://doi.org/10.1016/j.amjmed.2014.11.036 (2015).

35. Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *The New England journal of medicine* **341**, 709–717, https://doi.org/10.1056/nejm199909023411001 (1999).

36. Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *The New England journal of medicine* **348**, 1309–1321, https://doi.org/10.1056/NEJMoa0130207 (2003).

37. Cleland, J. G. et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. *European heart journal* **27**, 2338–2345, https://doi.org/10.1093/eurheartj/ehl230 (2006).

38. Wu, C. K. et al. Prognostic factors of heart failure with preserved ejection fraction: a 12-year prospective cohort follow-up study. *International journal of cardiology* **171**, 331–337, https://doi.org/10.1016/j.ijcard.2013.12.008 (2014).

39. Go, A. S. et al. Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice. *Archives of internal medicine* **168**, 2415–2421, https://doi.org/10.1001/archinternmed.2008.506 (2008).

40. Kramer, J. M. et al. Comparative effectiveness of beta-blockers in elderly patients with heart failure. *Archives of internal medicine* **168**, 2422–2428; discussion 2428–2432, https://doi.org/10.1001/archinternmed.2008.511 (2008).

41. Liu, F. et al. Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis. *PLoS One* **9**, e90555, https://doi.org/10.1371/journal.pone.0090555 (2014).

42. Patel, K. et al. Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes. *Int J Cardiol* **173**, 393–401, https://doi.org/10.1016/j.ijcard.2014.03.005 (2014).

43. Edelmann, F. et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. *Jama* **309**, 781–791, https://doi.org/10.1001/jama.2013.905 (2013).

44. Pandey, A. et al. Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review. *Journal of the American Heart Association* **4**, e002137, https://doi.org/10.1161/JAHA.115.002137 (2015).

45. Pitt, B. et al. Spironolactone for heart failure with preserved ejection fraction. *N. Engl. J. Med.* **370**, 1383–1392, https://doi.org/10.1056/NEJMoa1313731 (2014).

46. Patel, K. et al. Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. *JACC Heart Fail* **1**, 40–47, https://doi.org/10.1016/j.jchf.2012.08.001 (2013).

Acknowledgements

The study was supported by Taipei Veterans General Hospital (V100C-145, V101C-092, V102C-119, V103B-017, and V104C-172), Ministry of science and technology (MOST 103–2314-B-010-050-MY2), and Ministry of Health and Welfare, Taiwan grant (MOHW-105-TDU-B-211-133017, MOHW106-TDU-B-211-113001, MOHW107-TDU-B-211-123001), and the National Death Registry.

Author Contributions

Data collection was done by Shih-Hsien Sung. Manuscript was written by Shih-Hsien Sung, Ta-Jung Wang and Chen-Huan Chen. Statistical analysis was done by Ta-Jung Wang and Chao-Yu Guo. Data interpretation was done by Hao-Min Cheng, Wen-Chung Yu, Chao-Yu Guo, Chern-En Chiang. Chen-Huan Chen is the corresponding author.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-32684-9.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2018